DBV Technologies S.A. (DBV) Earnings Call Transcript & Summary

October 28, 2026

Euronext Paris FR Health Care Biotechnology earnings 39 min

Earnings Call Speaker Segments

Operator

operator
#1

Thanks for joining us for the DBV Technologies conference call covering third quarter 2026 results and a business update. <<operator_script>> Just a note that this event is being recorded. At this point I'll hand things over to Kevin Gardner of LifeSci Advisors. Kevin, the floor is yours.

Kevin Gardner

unknown
#2

Thank you. Earlier today, DBV Technologies released its financial results for Q3 2026. You can find this update in the Press Releases section on the DBV Technologies website. Before we get started, I want to remind everyone that this call may contain a number of forward-looking statements. These include, but are not limited to, comments about our forecast of estimated cash runway, our clinical and regulatory development plans, the design and conduct of our clinical trials, what we expect regarding the timing and results of interactions with regulatory agencies and their decisions, and the ability of any of our product candidates, if approved, to improve the lives of patients with food allergies. Such forward-looking statements rest on assumptions that carry risks and uncertainties, which could cause the company's actual results to differ significantly from what these statements suggest. In light of these risks and uncertainties, you should not place undue reliance on these forward-looking statements. For information about risk factors that could cause the company's actual results to differ materially from expectations — including any forward-looking statements made on this call — please refer to the company's filings with the SEC and the French AMF. Except as required by law, the company disclaims any obligation to publicly update or revise any forward-looking statements to account for or reflect events or circumstances occurring after this call.

Kevin Gardner

unknown
#3

Daniel Tasse, DBV's Chief Executive Officer, is with me on today's call. Daniel, I'll hand things over to you now.

Daniel Tassé

executive
#4

Thanks, Kevin, and I appreciate everyone being with us today. Joining me on this call are Virginie Boucinha, our CFO; Pharis Mohideen, our CMO; and Kevin Malobisky, our Chief Operations Officer. Product engineering and development fall under Kevin's remit. At DBV, he oversees manufacturing as well as quality. The third quarter of 2026 carried forward the effort that goes into transforming into a commercial organization. The quarter's standout event was submitting our BLA for 4 to 7-year olds, and for that I must offer a huge thank you to the DBV team, to our investigators, and to the food allergy community, all of whom have backed our efforts in an exceptional way. I'd also like to acknowledge the FDA's constructive engagement over the last few months and I look forward to collaborating closely with them throughout the review. Alongside this critical regulatory work, DBV's manufacturing and quality management teams have collaborated closely with Fareva Amboise, the company's contract manufacturing partner. That effort, involving extensive cooperation with third-party expert consultants, comes in the wake of the April 2026 FDA Warning Letter to Fareva. As we disclosed before, that letter stemmed from a September 2025 inspection concerning manufacturing of a veterinary product, and it contained certain observations centering on quality management operations and systems, which means the Warning Letter carries site-wide implications at Amboise.

Daniel Tassé

executive
#5

It makes sense that people might have questions about this and about what it means for how we review things and for the possible approval of the VIASKIN Peanut Patch in 4 to 7-year olds, and I'd like to spend part of our time today addressing those. So let me bring in Kevin to walk through more specifics on the remediation process and how we're getting ready for our Pre-Approval Inspection.

Kevin Malobisky

executive
#6

Thanks, Daniel. As Daniel said, I'm Kevin Malobisky, Chief Operations Officer at DBV. Just to give you a quick background: I've spent close to 40 years in pharma and biotech, with my career centered on regulatory affairs and quality programs, plus building and leading teams through innovative development and operations. I came to DBV roughly 4 years ago. And as Daniel noted, I head up the global quality, development, manufacturing and Reg CMC teams here. Let me begin by laying out the responsibility and the process for successfully resolving the Warning Letter that was received at Fareva Amboise. Full responsibility for adequately remediating the findings listed in the Warning Letter sits with the company that received it — here, that's Fareva Amboise. Since the Warning Letter came in last April, Fareva has accepted that responsibility and embraced it, and it is working alongside DBV and the third-party consultants we selected on the remediation plan for the elements that could apply to manufacturing the Peanut Patch. Remediating a Warning Letter is a well-established, standardized regulatory process, and I'd like to spend a few minutes walking you through it — how Fareva has responded to the FDA and how FDA — sorry, and how DBV has been involved in that remediation process.

Kevin Malobisky

executive
#7

There are four components here. To start, once we get a Warning Letter, our company has 15 days to send back a thorough written reply that lays out the remediation plan. That plan covers the corrective and preventative actions, or CAPAs, that we propose, along with how often we'll give the FDA written updates. Usually that happens every 30 or 60 days, continuing until remediation wraps up. In this instance, Fareva sent its written response and plan to the FDA inside the 15 business days, and since then it has been giving the Agency written updates on a monthly basis. Second, as you probably know, outside consultants and teams with remediation expertise typically support the remediation process. A lot of these specialists carry deep knowledge of quality management systems and frequently count former FDA personnel among them. When a question is highly technical or tied to a specific product, the remediation team is able to bring in extra subject matter experts. As I said earlier, DBV's manufacturing and quality management teams are collaborating closely with Fareva as well as third-party consultants on remediation efforts that have a direct impact on manufacturing of the VIASKIN Peanut Patch. Third, the work is run against a detailed project plan that the company's management team and the remediation experts developed jointly with the company's quality teams.

Kevin Malobisky

executive
#8

Everything is tracked against the plan, and that tracking forms the foundation for the monthly reports we send to the FDA. In this instance, Fareva gave DBV its detailed project plan, which let our expert teams and our consultants help with parts of the remediation plan that could apply to manufacturing VIASKIN Peanut Patches. Thanks to this cooperation, Fareva has been able to concentrate its resources on remediation across the whole site, while the DBV quality team also gained direct access and clear visibility into the work that matters most for producing the VIASKIN Peanut Patch. Last, as remediation moves forward and the company feels confident about the date on which remediation will be finished, they will ask the FDA to reschedule a reinspection. So what does all this mean for our BLA? To be clear, reviewing our application and remediating Fareva's Warning Letter are two separate, distinct processes. The point where they come together is the Pre-Approval Inspection, or PAI, and its readiness. As is standard with FDA filings, DBV put a target date for PAI readiness into the BLA submitted to the FDA. That target date for PAI readiness falls after the point when Fareva expects to have finished its remediation. This context matters for understanding how we are working together with Fareva and for reinforcing how committed we are to the remediation process with them, specifically regarding the elements relevant to the VIASKIN Peanut Patch.

Kevin Malobisky

executive
#9

Thanks for listening, and I'll now turn things back over to Daniel.

Daniel Tassé

executive
#10

Thank you, Kevin. It goes without saying that the work Kevin and his team are doing is a priority for the company, and it will stay that way until the remedial efforts -- the remediation efforts are complete. It's also very important that we don't lose sight of the progress being made across DBV, and I would now like to provide an update on our Toddler Program. Over the last few months, we have also discussed with FDA our upcoming filing in toddlers aged 1 to 3 years as we're preparing to submit our BLA for children aged 4-through-7 years. These discussions included a potential rolling submission of the 1-through-3 BLA. Now we welcome hearing the FDA's perspective as we have a very unique dynamic here. We have two distinct BLAs to be filed in relatively quick succession. As we previously stated, no analogs exist for VIASKIN Peanut Patch. It's novel. We are building a breakthrough therapy on unique biology and a novel mode of action. Now both BLAs share things and differ in many ways. Both BLAs share similar approaches to clinical development, although, it's an important although, although with two distinct populations and two large data sets. There are meaningful differences between the two clinical sectors.

Daniel Tassé

executive
#11

As you’re aware, VIASKIN Peanut is a drug-device combination that delivers a biological API. So for each BLA, both CMC modules are large and complex, even though there’s still meaningful overlap in content between the two. But everything I’m telling you here about what the two BLAs share and where they differ matters because, most importantly, the same FDA team will review both BLAs. And while there are clearly efficiencies in reviewing the two BLAs overall, we don’t want to cause a review bottleneck by forcing two BLAs through in parallel and potentially risk doing exactly that. Our aim is to achieve an expedient and efficient review of both BLAs. We’ve had discussions with the Agency, and in those discussions the Agency said that beginning the 1-through-3 review soon after the 4-through-7 review would let them build on the important learnings from the first review and also take advantage of the efficiencies we expect given the meaningful content overlap between the two BLAs. Beyond that, it would also give DBV and FDA a chance to align on the form, the content, and the best timing of the components of a 1-through-3 submission, all to support an efficient review of both BLAs.

Daniel Tassé

executive
#12

And DBV fully supports the FDA's approach. As a concrete illustration, we requested Priority Review for the 4-through-7 group, and we definitely do not want to divert FDA's focus from finishing that review first and finishing it efficiently. The efficiency of the later review of our 1-through-3 application will clearly gain from this well-coordinated sequential approach. We'll keep talking with the FDA over the coming few months and expect to file a toddler BLA in 2027. We will give an update once the FDA's discussions of these elements are finalized. And as a reminder, the FDA earlier issued written communication confirming an accelerated approval pathway for the VIASKIN Peanut Patch in toddlers. Now, before we open for questions, I'll ask Virginie to walk us through our third quarter financial results, cash position and highlights. Virginie?

Virginie Simone Jeanine Boucinha

executive
#13

Thanks, Daniel, and good afternoon, everyone. We closed the third quarter with USD 165.7 million in cash and cash equivalents. That figure includes $50 million in gross proceeds from sales of ADSs to RA Capital through our refreshed ATM program. After submitting the BLA, we revised our operating and liquidity forecast. Based on that, we estimate existing cash will fund operations into the third quarter of 2027. This forecast takes a stage-gated approach to investment. Our spending assumptions are tied to milestones, so the timing of certain expenditures lines up with regulatory developments, while we continue funding what the FDA review and a potential launch require. That means ongoing investments in Medical Affairs, Market Access, Marketing, Account Management and Pharmacovigilance, as well as in our launch infrastructure. Now turning to our P&L. Year-to-date operating expenses came in at USD 164 million -- USD 166.4 million, versus $107 million a year ago. That's an increase of $59.4 million. Roughly half of that increase went to the clinical and regulatory work behind the BLA filing itself. This investment also reflects ongoing advancements in COMFORT Toddlers, its open-label extension, the VITESSE open-label extension and THRIVE. The remaining half of our investments went toward building a commercial-ready company.

Virginie Simone Jeanine Boucinha

executive
#14

Our sales and marketing spend rose to $15.7 million from USD 1.9 million, reflecting the commercial know-how and launch capabilities we're putting in place. On top of that, we're continuing to build pre-commercial inventory and to scale up the corporate functions needed to support commercialization. Execution defined the third quarter for us. We filed the BLA and put down the groundwork to operate as a commercial organization, and we'll continue to pace our investment against regulatory milestones. With that, I'll hand things back to Daniel.

Daniel Tassé

executive
#15

Virginie, thank you. To wrap up, DBV took a significant step forward during the third quarter. Our BLA for children 4 through 7 has now been submitted, and our attention is on helping make the FDA review efficient, collaborating with Fareva, moving manufacturing readiness ahead, and getting ready for the possible commercialization of the VIASKIN Peanut Patch, should it be approved. At the same time, we are still dedicated to extending how far our technology might reach with younger children via our Toddler Program. We know there is important work in front of us. With clear priorities, energy and disciplined execution, we will move into the next phase. We look forward to updating you on how we are progressing. Operator, we are ready to open the line for questions now.

Operator

operator
#16

<<operator_script>> Our opening question is from Kristen Kluska at Cantor Fitzgerald.

Kristen Kluska

analyst
#17

Thanks for all the detail you gave us today about how manufacturing is progressing. I had a handful of questions on that front. Just to get the process straight: is Fareva passing along to you the monthly updates they put together — meaning what they send to the FDA and what feedback they've gotten back? And then, can you tell us whether the actual FDA reinspection has actually been scheduled yet? I'm also just trying to get a sense of when we, the public, might be able to learn when that will happen and, eventually, what the outcome turns out to be?

Daniel Tassé

executive
#18

Okay, Kristen, I'll handle that one. They do provide us with a substantial portion of the monthly report, but keep in mind they've got 70 customers and produce 100 products. Many of those details simply aren't meant for competitors or other companies to view. So we're fairly pleased with how much they do share. It's more than sufficient for us to feel confident about the progress, though for those reasons we don't have visibility into everything. Does that make sense? As for your second question, the FDA visit hasn't been scheduled yet, and scheduling it now would be somewhat premature. Again, as matters move forward, that's something we'll gladly share with investors as we reach those milestones. Does that address your question, Kristen?

Kristen Kluska

analyst
#19

Yes.

Operator

operator
#20

Sushila Hernandez from VLK has our next question.

Sushila Hernandez

analyst
#21

I just want to clarify — is Fareva at this point tracking its detailed plan? And is there enough time to carry out full remediation, with some potential buffer for potential delays, ahead of the preapproval inspection? And the second one: have you finished and analyzed the data from the COMFORT safety study in toddlers? And the last question — so is it then that you'll submit the toddler BLA only after a complete review of the children BLA? Could you elaborate on that?

Daniel Tassé

executive
#22

Thank you. For the final two questions about toddlers, Pharis is going to take those, and then we'll address your question regarding the remediation process after that. So, Pharis, would you take us through the current status on toddlers and the upcoming dialogue about the form in which that data gets submitted, given that this discussion isn't — hasn't yet fully happened with the Agency. So, Pharis?

Pharis Mohideen

executive
#23

Yes. So as you may remember, enrollment for COMFORT Toddler wrapped up during the second quarter. That trial is a supplemental 6-month safety study, so you can work out the timing from there. I think the key thing, as Daniel said, will involve our continuing discussions with the FDA about when the 1-to-3 BLA should come in relative to the 4-to-7. And to reinforce Daniel's point, we've stayed in close contact and ongoing dialogue with the FDA. The last thing we'd want is for the 1-to-3 to become a bottleneck or to delay their ability to grant Priority Review for the 4-to-7 BLA. Naturally, from a regulatory and legal perspective, nothing prevents us from submitting the BLA if we chose to, but that isn't the spirit of our relationship with the FDA. So I'm not certain whether that fully answered your question, Sushila, but I think what lies behind your question and what you're driving at is what Daniel already addressed.

Sushila Hernandez

analyst
#24

Yeah, that’s clear.

Daniel Tassé

executive
#25

Alright. And Sushila, could you ask your first question again? That way, if we provide a specific answer, we'd appreciate it.

Sushila Hernandez

analyst
#26

Yeah. So, is Fareva following the detailed plan they set out? Are all the steps on schedule? And is there enough time for full remediation before the Pre-Approval Inspection?

Daniel Tassé

executive
#27

I’ll let <<inaudible>> Kevin handle that question. So, Kevin?

Kevin Malobisky

executive
#28

Thanks, Daniel. Yes. So like I said, we collaborate extremely closely with Fareva, along with quite a few consultants, on a daily basis, and we feel quite good about how they're progressing when it comes to the remediation. As for when that reinspection happens relative to the timing of our PAI, we also feel very comfortable about that, in terms of the buffer that would be in place.

Operator

operator
#29

The next person to ask something is Jon Wolleben from Citizens.

Jon Wolleben

analyst
#30

I may have missed it, but could you go over what was in the Warning Letter, and which remediation efforts are still underway? Then, any thinking on bringing in a second manufacturer for redundant supply? Or is that a bit too late in the game now?

Daniel Tassé

executive
#31

I'll begin with the latter part, and Kevin will address the remediation process question. Somewhere in the world, we require a second manufacturing unit to support the remaining years in the forecast we provided to investors. So additional capacity is needed, though that investment is being made to support the complete site of the product upon approval. Establishing a new facility requires roughly 3 years, whether that's a CDMO or one of your own sites. Clearly, then, that isn't the backup plan for Fareva. With Fareva, our plan — and we're confident in it — is to complete the remediation and essentially launch the product using their capacity. Is that clear? On your first question, Kevin, can you respond? Or does Jon need to restate it for you?

Kevin Malobisky

executive
#32

Yes, I can address that. As Daniel mentioned earlier, the FDA inspection that resulted in the Warning Letter centered on a veterinary product and an aseptic manufacturing process at the site. That matter is entirely separate from the ongoing work on the VIASKIN Peanut Patch. That said, the remediation involves a site-wide review of possible impacts to aseptic filling, and whether the citations tied to that may or may not be connected is part of what the remediation is addressing. And once again, we feel very good about the progress Fareva is making and about the expertise we have available to keep monitoring it closely.

Daniel Tassé

executive
#33

Also, Jon, that Warning Letter is publicly accessible, and we can spare you a few mouse clicks by sending it over. Essentially, it lays out precisely that, plus observations regarding overall quality management systems and training—though those kinds of remarks are typical in a Warning Letter. And whenever a comment like that appears, it clearly affects every product manufactured at that site rather than being confined just to the initial observation, which involved this veterinary product. Hopefully that answers your question helpfully.

Operator

operator
#34

<<operator_script>> Our following question is from Yatin Suneja at Guggenheim Partners.

Yatin Suneja

analyst
#35

Thanks for all that detail. So — I don’t actually have a question about the CRO or the CMC. What I’m more focused on is: what are you expecting at this point? Is a Priority Review still your expectation? Since that pathway moves faster, if a Priority Review comes through, do you believe there’s enough time to work through all of those items? Then the second part: if you do get one — would you — are you also entitled to a Priority Review voucher? And how are you thinking about potentially monetizing it should one be granted?

Daniel Tassé

executive
#36

Appreciate the two questions. Let me get on here. Yatin, what was the first part of your question again? The second one concerns the priority voucher, and then the market...

Yatin Suneja

analyst
#37

Yeah. On the first one, it's more about whether you're still anticipating a Priority Review for this application.

Daniel Tassé

executive
#38

Yes. Thanks very much. Yes, we do. Given our breakthrough designation, we qualify for Priority Review. At the Agency, the call on granting Priority Review to a breakthrough product isn't made by the Review division — it sits with a separate team at the FDA. So that decision gets made independently of the Review division. So the request has been submitted. A large percentage of companies holding breakthrough designation do receive Priority Review. So that's still our hope here, and I'd say our expectation, but really it's our hope here. All of our planning — whether that's launch planning or whether it's remediation and preparation for the PAI — hinges on what would be a Priority Review. So we aren't giving ourselves any extra buffer time here. We're planning for the best case scenario, which is a tight timeline. We remain comfortable that all of it can be managed within the clock of Priority Review. On your second question, the rules under which we could monetize access to a pediatric voucher would assume that the population, obviously, is less than what the target population is, so 250,000 to 300,000 kids, arguably 1-to-3 is a bit less than that.

Daniel Tassé

executive
#39

The Priority Review rules, though, are built on the assumption that the technology isn’t usable in other populations—and that’s clearly the very last thing we’d want to accept with VIASKIN Peanut. Our view is that we can serve kids aged 1 to 7, and also kids once they’re past 7, since they remain eligible for therapy. So regrettably, the strictest reading of the priority voucher criteria wouldn’t cover VIASKIN Peanut, and it isn’t for want of trying. <<inaudible>> can respond to your question. And after that...

Yatin Suneja

analyst
#40

And then perhaps just one more question. Yes. No, that's really helpful. Then one additional question, if I may, regarding the commercial side. Maybe you could discuss some of the preparation underway on the commercial front. What kind of team are you able now to bring on board? I understand the bulk of the sales force arrives after or nearer to launch. But perhaps speak to that — when might you be launch ready?

Daniel Tassé

executive
#41

Yes. Kevin Trapp isn't with us on this call. He'd clearly be the ideal person to field those questions, but I've been in close contact and working alongside him throughout. So, to hit the main points: as you're aware, 4,500 allergists practice in the U.S. They handle the majority of food allergy patients, peanut included. We're envisioning a sales force sized at 50 to 70 people to call on them. Parents matter a great deal in the commercial picture here. So our capacity to construct the proper mechanism, the proper outreach to media, and to open a dialogue with them forms a major piece of our marketing plan, and so too, clearly, does engaging with payers to ensure not just that we secure a price we consider fair for the therapy, but also a review or prioritization process on the part of allergists that stays relatively straightforward. So those are all key elements of our marketing plan here. And as you could see from our P&L covering the first 9 months of the year, we're deploying those investments wisely. Clearly, building up inventory in preparation for launch arrives somewhat later on. Clearly, bringing a sales force on board arrives near the end of the process.

Daniel Tassé

executive
#42

However, a lot of the crucial investments we're making at this moment stem from the fact that you can't launch a blockbuster with 6 weeks of preparation — a blockbuster gets launched with 18 months of preparation. I think we're simply being very smart, very strategic, and very, very planful when it comes to making those investments as we move forward toward derisking the product vis-à-vis theAgency. Hopefully, that was helpful.

Operator

operator
#43

Sam Slutsky from LifeSci Capital has our next question.

Samuel Slutsky

analyst
#44

I’ve got two questions. First, does the breakthrough therapy designation and the possibility of Priority Review also cover the 1-to-3 group, or does that apply only to the 4-to-7 age range? Second, regarding COMFORT Toddlers, is that essentially just a box-checking press release about higher safety that we hope will match earlier studies? Or is there something more we might see in that release?

Daniel Tassé

executive
#45

Yeah, so I'll start with the headline results for the toddlers. On your first question, whether a single breakthrough designation could support two BLAs is untested — so this is uncharted territory for us. But we do have the opportunity, given our accelerated approval pathway in 1-to-3, which also comes with eligibility for Priority Review in that process. So what we're thinking right now is that Priority Review as a function of breakthrough designation supports the request made in 4-to-7, and then the other one would come with the accelerated approval pathway offered in 1-to-3. To be very clear, I'm sharing with you what our thinking is here. We don't have those answers. We don't have those commitments from the Agency yet. Does that make sense?

Samuel Slutsky

analyst
#46

Yeah. And then regarding your second question...

Daniel Tassé

executive
#47

Was the entire question included in that, or not quite?

Samuel Slutsky

analyst
#48

That covered the first question. Now, on the second one, which was about COMFORT Toddlers: do you think that will essentially be a box-checking press release simply stating that safety is, hopefully, in line, or what do you expect that press release to contain?

Daniel Tassé

executive
#49

Yes. We'll clearly issue a press release with the results here because — and I'll ask Pharis to chime in on this. The pivotal study is EPITOPE. It has finished. This is a supplemental safety study. There are numerous ways to give that to the FDA as part of the BLA, including as a safety update later in the process here. All those discussions will happen with the Agency going forward. But yes, I believe it would be sensible for us to announce the results once we have them to say the study completed. And also, we expect that we'll show no safety data that would be a deviation we've seen historically, but I'll invite Pharis to add his 2 cents worth here since this study — and it's his publication team.

Pharis Mohideen

executive
#50

Thanks, Daniel. That conclusion is one I'd share. Sam, over the years we've built a database of roughly 2,000 patients, and this product is very well characterized. So if anything did come of that, it would be very out of character for the product, which we don't expect. So to answer your question directly, it would pretty much be a check-the-box type of press release. As you know, for the safety studies, at least for the nature of the safety studies we do, there's no primary endpoint, and it's not powered to show a specific thing. So it's all about meeting exposure numbers for the product. So very much, in my mind, at this point, a check-the-box type of press release.

Operator

operator
#51

Gavin Clark-Gartner from Evercore ISI has our next question.

Gavin Clark-Gartner

analyst
#52

Thanks for the manufacturing updates. I'll stay on that topic as well. Could you take us through the scope of the updates and the timelines for what you expect to report to us over the next 6 or 7 months as the review moves forward? You have the remediation activities, and I noticed in the 10-Q there's a mock PAI, a small milestone with the February 1 date listed. Obviously I have that down for when the PAI gets scheduled. So I'm just wondering what we should expect to hear from you over the next 6 or 7 months?

Daniel Tassé

executive
#53

Right. Let me be sure I'm clear here so nothing gets misread. The date we've given the FDA, the one we've told them we'd be inspection-ready for, is February 1. Before that point, there will be mock PAI. Manufacturers commonly run mock inspections on a regular basis—some unannounced, some scheduled. That's how we ensure our CDMO remains sharp. Incidentally, we follow the same practice at our own plant. So a number of inspections will occur along the way, all to confirm readiness. And clearly, those developments may turn out to be relevant, and they may be something we decide to share with the market as the dossier moves forward here. Does that address your question?

Gavin Clark-Gartner

analyst
#54

That's useful. Yeah, it is.

Operator

operator
#55

<<operator_script>> Theodora Beadle from Goldman Sachs has our next question.

Theodora Beadle

analyst
#56

To start, how far along are your conversations with payers already, given the possible approval of VIASKINPeanut? And what kind of early feedback have you gotten from that process? Then second, how should we think about first-year sales potential for VIASKIN Peanut in the 4-to-7-year-old age group?

Daniel Tassé

executive
#57

Yes. I'll take your second question first. Guidance is not something we'll be giving. Obviously, as launch gets nearer, there will be a launch day for investors and analysts, and Kevin Trapp will do a masterful job taking you guys through how we think about the market, so they can help us track it alongside us here. Regarding conversations with payers, at this point in time I see that as obviously relatively limited. It's part of launching a product. It's among the investments we should make ahead of a product launch — to understand everything about payer and payer dynamics, everything from health economic outcome research arguments for the price as well as analysis, as well as understanding what the prior authorization process would be, which is likely given the nature of the product and of the indication. Those discussions have been going on. We have account managers talking to all the big payers in the U.S. already. And all of this has been folded into what is, as you know, a commercial strategy where outreach and coordination with payers is a big part of the value creation. But I'm very pleased with the efforts that Kevin and his team have led on that front.

Daniel Tassé

executive
#58

I believe that addresses what you asked.

Operator

operator
#59

That brings our Q&A portion to an end. I'll now hand things back to CEO Daniel Tasse for some closing comments.

Daniel Tassé

executive
#60

Carl, thank you — nice work. Everyone, thanks for being with us today. We appreciate the analysts' questions. That wraps up our call for this afternoon. Thank you for your time. Thank you for your engagement, and enjoy a wonderful evening. We'll speak with you soon.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete DBV Technologies S.A. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to DBV Technologies S.A. earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in DBV Technologies S.A. or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.